Schering holds off on Clarinex push

Published on .

Schering-Plough Corp. again will spend aggressively to promote its blockbuster allergy drug Claritin. Schering was preparing to shift its focus to Claritin successor Clarinex, but last week said the U.S. Food & Drug Administration made approval of the new drug contingent on Schering resolving FDA issues with its manufacturing and quality control. A company spokes-man said Schering doesn't comment on marketing plans.

Copyright February 2001, Crain Communications Inc.

Most Popular
In this article: